+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Active Implantable Medical Devices Market - Growth, Trends, and Forecasts (2020 - 2025)

  • PDF Icon


  • 111 Pages
  • June 2020
  • Region: Global
  • Mordor Intelligence
  • ID: 4896129
Global Active Implantable Medical Devices market is expected to witness a CAGR of 7.2% during the forecast period. Certain factors that are driving the market growth include increasing burden of cardiovascular and neurological diseases and investments and funds to develop technologically advanced products.

Increasing geriatric population is one of the important drivers propelling the growth of the market. The number of people aged 65 or older is projected to increase from 524 million in 2010, to nearly 1.5 billion in 2050, representing about 16% of the world’s population. Furthermore, increasing chronic diseases coupled with the advancements in the active implantable medical devices are projected to boost the market growth. However, rising demand for non-invasive procedures, issues related to implantable devices and high cost of the devices anticipated to impede the market growth.

Key Market Trends

Implantable Cardiac Pacemaker is Expected to Witness Healthy Growth Over the Forecast Period

The implantable pacemakers are of three major types, namely, single-chamber, dual-chamber, and biventricular pacemakers. The growth of the segment can be attributed to factors, such as reduced post-surgical complications and the presence of multiple leads in order to assure normal physiology of the heart.

According to the American College of Cardiology, cardiovascular disease (CVD) accounted for 800,000 deaths in the United States in 2017 alone. Among Americans, an average of one person dies from cardiovascular disease, every 40 seconds. Coronary heart disease (CHD) accounts for the majority of CVD deaths, followed by stroke and heart failure. According to the European Heart Network, every year, cardiovascular disease (CVD) causes 3.9 million deaths in Europe and over 1.8 million deaths in the European Union (EU). The implantable pacemaker segment is growing rapidly, due to increasing R&D funding for healthcare and increasing R&D trends in emerging economies.

North America Dominates the Market and Expected to do Same in the Forecast Period

The rising prevalence of cardiovascular diseases, high obesity rates, and favorable reimbursement environments are the primary factors which are driving the market growth. According to American Heart Association (AHA) estimates about 5.7 million adults in the United States are suffering from congestive heart failure. And about one in nine deaths include heart failure as contributing cause. As per Centers for Disease Control and Prevention (CDC) statistics, more than three million people in the United States suffer from atrial fibrillation, which is the most common type of abnormal heart rhythm. Furthermore, the number is expected to quadruple by 2050, as the population ages.

Furthermore, in the region, several trails are being conducted on different types of hearing aids. Hospital and medical centres, along with research institutes, collaborated with companies across the world. Nearly 15% of the population is above 65 years, who primarily require these devices.

Competitive Landscape

The global Active Implantable Medical Devices market is moderately competitive and consists of a few major players.

In November 2017, Medtronic PLC has announced U.S. Food and Drug Administration (FDA) approval and U.S. commercial launch for its portfolio of Azure pacemakers with BlueSync technology. Available in both single chamber and dual chamber models, the Azure XT MRI and Azure S MRI pacemakers offer improved longevity, estimated at 13.7 years (dual chamber) or 27 percent longer than its previous version.

Companies like Abbott Laboratories, Biotronik Se & Co., Kg, Boston Scientific Corporation, Cochlear Limited, Livanova PLC, Med-EL, Medtronic PLC, Nurotron Biotechnology Co. Ltd., William Demant Holding A/S, among others, hold the substantial market share in the Active Implantable Medical Devices market.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Burden of Cardiovascular and Neurological Diseases
4.2.2 Investments and Funds to Develop Technologically Advanced Products
4.3 Market Restraints
4.3.1 Issues Related to the Use of Implantable Medical Devices
4.3.2 High Cost of Implants and Stringent Regulations
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Product
5.1.1 Implantable Cardioverter Defibrillators
5.1.2 Implantable Cardiac Pacemakers
5.1.3 Ventricular Assist Devices
5.1.4 Implantable Heart Monitors/Insertable Loop Recorders
5.1.5 Neurostimulators
5.1.6 Implantable Hearing Devices
5.1.7 Others
5.2 Geography
5.2.1 North America United States Canada Mexico
5.2.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.2.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.2.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.2.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Biotronik Se & Co., Kg
6.1.3 Boston Scientific Corporation
6.1.4 Cochlear Limited
6.1.5 Livanova PLC
6.1.6 Med-EL
6.1.7 Medtronic PLC
6.1.8 Nurotron Biotechnology Co. Ltd.
6.1.9 William Demant Holding A/S

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Abbott Laboratories
  • Biotronik Se & Co., Kg
  • Boston Scientific Corporation
  • Cochlear Limited
  • Livanova PLC
  • Med-EL
  • Medtronic PLC
  • Nurotron Biotechnology Co. Ltd.
  • William Demant Holding A/S